Yuta Hasegawa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yuta Hasegawa has a total of 269 co-authors. Here are the top co-authors by number of shared publications:
Takahiro Fukuda
Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan
9 shared publications- Takanori Teshima
Department of Hematology, Hokkaido University Faculty of Medicine, Sapporo, Japan
9 shared publications - Yoshiko Atsuta
Japanese Data Center for Hematopoietic Cell Transplantation Nagakute Aichi Japan
9 shared publications - Daigo Hashimoto
Department of Hematology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan
8 shared publications Hiroyuki Ohigashi
Department of Hematology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan
7 shared publications- Noriko Doki
Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital Tokyo Japan
6 shared publications
Latest Publications
- 5 November 2026
- Published by American Society of Hematology in Blood
- Vol. 148 (19) , 2423-2435
Early administration of calcineurin inhibitors limits the tolerogenic effect of PTCy in allogeneic hematopoietic transplant
We recently demonstrated that early administration of calcineurin inhibitors (CNIs) after murine allogeneic hematopoietic cell transplantation (allo-HCT) inhibits terminal exhaustion of donor T cells and hampers tolerance induction. However, the role of CNIs in regulating T-cell exhaustion in clinical allo-HCT remains to be clarified. It also remains to be elucidated why posttransplant cyclophosphamide (PTCy) can reduce chronic graft-versus-host disease (cGVHD), despite the administration of CNIs. In this study, we explored the impact of CNIs on donor T-cell exhaustion after PTCy-based haploidentical HCT. In mice, early administration of cyclosporine before PTCy preserved a population of Ly6C+ donor T cells with less exhausted characteristics, as has been shown in non-PTCy allo-HCT. In single-cell analyses of clinical samples from patients undergoing HLA-haploidentical peripheral blood stem cell transplantation with PTCy (PTCy-haplo-PBSCT), early administration of tacrolimus before PTCy promoted the expansion of effector-like CD8+ intermediate-exhausted T cells (Tex-int) and CD4+ cytotoxic T cells (CTLs), with the former enriched for both effector- and exhaustion-associated gene signatures, whereas the latter for effector- and CD4+ CTL–specific gene signatures. These subsets retained high responsiveness to T-cell receptor stimulation and PD-1 blockade, and their expansion on day 28 predicted subsequent cGVHD. In contrast, delaying tacrolimus administration until day 5 after PTCy-haplo-PBSCT significantly reduced the expansion of these effector-like T cells. These findings indicate that early CNI exposure favors the persistence of incompletely exhausted and clonally expanded donor T cells with pathogenic potential. Tex-int and CD4+ CTLs may serve as prognostic biomarkers of cGVHD risk and as promising targets for preemptive therapy for cGVHD.
- 5 November 2026
- Published by American Society of Hematology in Blood
- Vol. 148 (19) , 2423-2435
Early administration of calcineurin inhibitors limits the tolerogenic effect of PTCy in allogeneic hematopoietic transplant
We recently demonstrated that early administration of calcineurin inhibitors (CNIs) after murine allogeneic hematopoietic cell transplantation (allo-HCT) inhibits terminal exhaustion of donor T cells and hampers tolerance induction. However, the role of CNIs in regulating T-cell exhaustion in clinical allo-HCT remains to be clarified. It also remains to be elucidated why posttransplant cyclophosphamide (PTCy) can reduce chronic graft-versus-host disease (cGVHD), despite the administration of CNIs. In this study, we explored the impact of CNIs on donor T-cell exhaustion after PTCy-based haploidentical HCT. In mice, early administration of cyclosporine before PTCy preserved a population of Ly6C+ donor T cells with less exhausted characteristics, as has been shown in non-PTCy allo-HCT. In single-cell analyses of clinical samples from patients undergoing HLA-haploidentical peripheral blood stem cell transplantation with PTCy (PTCy-haplo-PBSCT), early administration of tacrolimus before PTCy promoted the expansion of effector-like CD8+ intermediate-exhausted T cells (Tex-int) and CD4+ cytotoxic T cells (CTLs), with the former enriched for both effector- and exhaustion-associated gene signatures, whereas the latter for effector- and CD4+ CTL–specific gene signatures. These subsets retained high responsiveness to T-cell receptor stimulation and PD-1 blockade, and their expansion on day 28 predicted subsequent cGVHD. In contrast, delaying tacrolimus administration until day 5 after PTCy-haplo-PBSCT significantly reduced the expansion of these effector-like T cells. These findings indicate that early CNI exposure favors the persistence of incompletely exhausted and clonally expanded donor T cells with pathogenic potential. Tex-int and CD4+ CTLs may serve as prognostic biomarkers of cGVHD risk and as promising targets for preemptive therapy for cGVHD.
- 26 July 2026
- Published by Wiley in British Journal of Haematology
- Vol. 209 (4) , 1797-1806
Donor age as a dual‐risk factor for donor safety and recipient survival in allogeneic haematopoietic stem cell transplantation
Summary: Donor selection in allogeneic haematopoietic stem cell transplantation (allo‐HSCT) requires balancing donor safety and recipient survival. We aimed to identify dual—association donor factors (DADFs)—donor characteristics associated with both increased serious adverse events (SAEs) and inferior patient survival—using umbilical cord blood (UCB) as a donor‐safety benchmark. This nationwide retrospective cohort study analysed Japanese registry data (2013–2022) including 22 892 donors and 29 559 recipients. Logistic regression identified donor SAE risk factors, while patient outcomes were evaluated using inverse probability of treatment weighting (IPTW)‐adjusted Cox models with UCB as reference. Propensity score matching (PSM) compared UCB with older donor haploidentical transplantation using post‐transplant cyclophosphamide (OD‐PTCy‐Haplo). Among donors, 93 (0.41%) experienced an SAE. Older donor age and female sex were independent risk factors for SAE. In IPTW‐adjusted analyses, allo‐HSCT from older haploidentical donors was associated with inferior overall survival (OS) and relapse‐free survival (RFS) compared with UCB. In PSM analyses of elderly high‐risk recipients, OD‐PTCy‐Haplo resulted in significantly worse OS and RFS than UCB. Older donor age emerged as a donor characteristic associated with increased donor SAE risk and inferior patient survival, particularly in haploidentical transplantation. UCB may offer a more favourable balance between donor safety and patient outcomes in selected high‐risk settings.
- 26 July 2026
- Published by Wiley in British Journal of Haematology
- Vol. 209 (4) , 1797-1806
Donor age as a dual‐risk factor for donor safety and recipient survival in allogeneic haematopoietic stem cell transplantation
Summary: Donor selection in allogeneic haematopoietic stem cell transplantation (allo‐HSCT) requires balancing donor safety and recipient survival. We aimed to identify dual—association donor factors (DADFs)—donor characteristics associated with both increased serious adverse events (SAEs) and inferior patient survival—using umbilical cord blood (UCB) as a donor‐safety benchmark. This nationwide retrospective cohort study analysed Japanese registry data (2013–2022) including 22 892 donors and 29 559 recipients. Logistic regression identified donor SAE risk factors, while patient outcomes were evaluated using inverse probability of treatment weighting (IPTW)‐adjusted Cox models with UCB as reference. Propensity score matching (PSM) compared UCB with older donor haploidentical transplantation using post‐transplant cyclophosphamide (OD‐PTCy‐Haplo). Among donors, 93 (0.41%) experienced an SAE. Older donor age and female sex were independent risk factors for SAE. In IPTW‐adjusted analyses, allo‐HSCT from older haploidentical donors was associated with inferior overall survival (OS) and relapse‐free survival (RFS) compared with UCB. In PSM analyses of elderly high‐risk recipients, OD‐PTCy‐Haplo resulted in significantly worse OS and RFS than UCB. Older donor age emerged as a donor characteristic associated with increased donor SAE risk and inferior patient survival, particularly in haploidentical transplantation. UCB may offer a more favourable balance between donor safety and patient outcomes in selected high‐risk settings.
- 8 July 2026
- Published by Elsevier in Cytotherapy
- Vol. 28 (11)
Haploidentical Transplantation versus Umbilical Cord Blood Transplantation in Acute Myeloid Leukemia with Measurable Residual Disease
- 8 July 2026
- Published by Elsevier in Cytotherapy
- Vol. 28 (11)
Haploidentical Transplantation versus Umbilical Cord Blood Transplantation in Acute Myeloid Leukemia with Measurable Residual Disease
- 27 May 2026
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (10) , 1287.e1-1287.e11
The Impact of Female-To-Male Allogeneic Hematopoietic Cell Transplantation on Survival Outcomes Varies by Recipient Age
- 27 May 2026
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (10) , 1287.e1-1287.e11
The Impact of Female-To-Male Allogeneic Hematopoietic Cell Transplantation on Survival Outcomes Varies by Recipient Age
- 27 April 2026
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 32 (6) , 102980
Perioperative pharmacokinetics of lenacapavir during massive hemorrhage in a patient with hemophilia a undergoing liver transplantation
- 27 April 2026
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 32 (6) , 102980
Perioperative pharmacokinetics of lenacapavir during massive hemorrhage in a patient with hemophilia a undergoing liver transplantation
- Open Access
- 20 April 2026
- Published by Springer Nature in Annals of Hematology
- Vol. 105 (5) , 255
HLA-matched versus haploidentical donor transplantation with post-transplant cyclophosphamide: a study on behalf of the donor/source working group of the Japanese society for transplantation and cellular therapy
Post-transplant cyclophosphamide (PTCy) is now being increasingly applied to HLA-matched donor (MD) transplantation. Prior studies in Western countries have demonstrated that allogeneic hematopoietic cell transplantation (allo-HCT) employing PTCy yields better outcomes with HLA-matched donors (MDs) than with haploidentical donors (HIDs). However, the effect of HLA mismatch may differ among racial groups. We retrospectively analyzed adult patients with hematological malignancies who underwent their first allo-HCT with PTCy from MDs or HIDs registered to the Japanese registry database between 2013 and 2021. Among 63 (related, n = 33; unrelated, n = 30) and 1261 patients who received MD and HID allo-HCT with PTCy, 50 (related, n = 30; unrelated, n = 20) and 100 patients were assigned to MD and HID groups by 1:2 propensity score matching (PSM). The results showed that MD recipients had better neutrophil recovery (hazard ratio [HR], 1.48; 95% confidence interval [CI], 1.04–2.10; P = 0.031) and lower risk of non-relapse mortality (NRM) (HR, 0.19; 95% CI, 0.05–0.81; P = 0.024) than HID recipients. Multivariable analyses in the entire cohort before PSM confirmed these findings. Fatal infection was the primary cause of NRM in the HID group. This study is the first to demonstrate that, within a homogeneous Asian cohort, MD may have an advantage over HID in PTCy-based allo-HCT in facilitating neutrophil engraftment and reducing the risk of NRM.
- 20 April 2026
- Published by Springer Nature in Annals of Hematology
- Vol. 105 (5) , 255
Open AccessHLA-matched versus haploidentical donor transplantation with post-transplant cyclophosphamide: a study on behalf of the donor/source working group of the Japanese society for transplantation and cellular therapy
Post-transplant cyclophosphamide (PTCy) is now being increasingly applied to HLA-matched donor (MD) transplantation. Prior studies in Western countries have demonstrated that allogeneic hematopoietic cell transplantation (allo-HCT) employing PTCy yields better outcomes with HLA-matched donors (MDs) than with haploidentical donors (HIDs). However, the effect of HLA mismatch may differ among racial groups. We retrospectively analyzed adult patients with hematological malignancies who underwent their first allo-HCT with PTCy from MDs or HIDs registered to the Japanese registry database between 2013 and 2021. Among 63 (related, n = 33; unrelated, n = 30) and 1261 patients who received MD and HID allo-HCT with PTCy, 50 (related, n = 30; unrelated, n = 20) and 100 patients were assigned to MD and HID groups by 1:2 propensity score matching (PSM). The results showed that MD recipients had better neutrophil recovery (hazard ratio [HR], 1.48; 95% confidence interval [CI], 1.04–2.10; P = 0.031) and lower risk of non-relapse mortality (NRM) (HR, 0.19; 95% CI, 0.05–0.81; P = 0.024) than HID recipients. Multivariable analyses in the entire cohort before PSM confirmed these findings. Fatal infection was the primary cause of NRM in the HID group. This study is the first to demonstrate that, within a homogeneous Asian cohort, MD may have an advantage over HID in PTCy-based allo-HCT in facilitating neutrophil engraftment and reducing the risk of NRM.
- 8 December 2025
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 32 (1) , 102888
Letermovir prophylaxis and risk of bacterial or fungal infection after allogeneic hematopoietic cell transplantation
- 8 December 2025
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 32 (1) , 102888
Letermovir prophylaxis and risk of bacterial or fungal infection after allogeneic hematopoietic cell transplantation
- 6 November 2025
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (3) , 339.e1-339.e9
Safety and Efficacy of Graft-versus-Host Disease Prophylaxis with Mini-Dose Methotrexate in Umbilical Cord Blood Transplantation: An NJHSG-CBT18 Observational Study
- 6 November 2025
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (3) , 339.e1-339.e9
Safety and Efficacy of Graft-versus-Host Disease Prophylaxis with Mini-Dose Methotrexate in Umbilical Cord Blood Transplantation: An NJHSG-CBT18 Observational Study
- 4 September 2025
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 31 (12) , 1008.e1-1008.e11
Risk Stratification Using Dynamic International Prognostic Scoring System and Splenomegaly in Myelofibrosis Treated with Pretransplant JAK Inhibitors
- 4 September 2025
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 31 (12) , 1008.e1-1008.e11
Risk Stratification Using Dynamic International Prognostic Scoring System and Splenomegaly in Myelofibrosis Treated with Pretransplant JAK Inhibitors